Sagimet Biosciences (SGMT) Other Non-Current Liabilities (2022 - 2023)
Sagimet Biosciences (SGMT) posted quarterly Other Non-Current Liabilities of $1000.0 for Q3 2023, down 80.0% quarter-over-quarter from $5000.0 in Q2 2023.
Powered by 
Analysis
Sagimet Biosciences (SGMT) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends
Sagimet Biosciences' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1000.0 for Q3 2023.
- In Q3 2023, Other Non-Current Liabilities changed N/A year-over-year to $1000.0; the TTM figure through Sep 2023 stood at $1000.0 (changed N/A YoY), while the FY2022 annual figure was $4000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q3 2023 stood at $1000.0, down from $5000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $5000.0 in Q2 2023, with the low at $1000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Sagimet Biosciences | 576.56 Mn | 576.56 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Dec 31, 2022 | 4,000.00 |